Free Trial
OTCMKTS:BIXT

Bioxytran (BIXT) Stock Price, News & Analysis

$0.12
-0.01 (-7.81%)
(As of 07/19/2024 ET)
Today's Range
$0.12
$0.12
50-Day Range
$0.08
$0.15
52-Week Range
$0.07
$0.35
Volume
1,000 shs
Average Volume
104,552 shs
Market Capitalization
$20.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BIXT stock logo

About Bioxytran Stock (OTCMKTS:BIXT)

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

BIXT Stock Price History

BIXT Stock News Headlines

Brace Yourself: Experts calling for Bitcoin to hit $100k
For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.
Bioxytran Gets Broad Patent Coverage on 60+ Viruses
Brace Yourself: Experts calling for Bitcoin to hit $100k
For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.
See More Headlines
Receive BIXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
7/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:BIXT
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Net Income
$-4,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.02) per share

Miscellaneous

Free Float
53,161,000
Market Cap
$20.92 million
Optionable
Not Optionable
Beta
-0.85
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. David Platt Ph.D. (Age 71)
    Chairman, CEO & President
    Comp: $420k
  • Mr. Ola Soderquist C.M.A. (Age 62)
    C.P.A., CM&AA, CMA, CPA, M.B.A., CFO, Treasurer & Secretary
    Comp: $420k
  • Mr. Michael Sheikh B.S. (Age 54)
    Chief Communication Officer
    Comp: $280k

BIXT Stock Analysis - Frequently Asked Questions

How have BIXT shares performed this year?

Bioxytran's stock was trading at $0.15 at the beginning of the year. Since then, BIXT shares have decreased by 21.3% and is now trading at $0.1181.
View the best growth stocks for 2024 here
.

How do I buy shares of Bioxytran?

Shares of BIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Bioxytran own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioxytran investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT) and Abiomed (ABMD).

This page (OTCMKTS:BIXT) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners